↓ Skip to main content

Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report

Overview of attention for article published in Oncology, February 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
29 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report
Published in
Oncology, February 2016
DOI 10.1159/000444186
Pubmed ID
Authors

François Pinquié, Gonzagues de Chabot, Thierry Urban, José Hureaux

Abstract

Erlotinib maintenance treatment improves progression-free survival compared with observation after first-line chemotherapy in unselected advanced non-small cell lung cancer (NSCLC). Very few cardiac adverse effects have been observed in phase III studies on tyrosine kinase inhibitors (TKI). We report the case of a 71-year-old woman with metastatic NSCLC treated with cisplatin/pemetrexed and then erlotinib maintenance therapy. After 26 months of TKI therapy, she developed dilated cardiomyopathy. Despite symptomatic treatment, left ventricular ejection fraction decreased to 25%. Ischemic heart disease was excluded by coronary angiography and cardiac magnetic resonance imaging, and no other cause was found. Erlotinib was stopped, and cardiac resynchronization therapy by pacemaker was initiated. This case report highlights the possible cardiotoxic effects of long-term erlotinib and suggests the need for close clinical and echocardiographic follow-up of patients receiving long-term TKI therapy.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 3%
Unknown 28 97%

Demographic breakdown

Readers by professional status Count As %
Other 6 21%
Student > Doctoral Student 5 17%
Student > Bachelor 3 10%
Researcher 3 10%
Student > Ph. D. Student 3 10%
Other 4 14%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 16 55%
Pharmacology, Toxicology and Pharmaceutical Science 4 14%
Nursing and Health Professions 2 7%
Computer Science 1 3%
Unknown 6 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 February 2016.
All research outputs
#18,441,836
of 22,849,304 outputs
Outputs from Oncology
#1,147
of 1,590 outputs
Outputs of similar age
#216,477
of 298,010 outputs
Outputs of similar age from Oncology
#29
of 40 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,590 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,010 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.